Joint Press Release: Synairgen and Aerogen Announce Strategic Partnership to Advance Inhaled Therapy for Severe Respiratory Infections
Southampton, UK & Galway, Ireland - 12 November 2025
Synairgen Research Limited, a clinical-stage biopharmaceutical company developing a pioneering inhaled antiviral therapy and Aerogen Ltd., the global leader in acute care aerosol drug delivery, are pleased to announce a strategic partnership to develop and deliver a custom aerosol device for Synairgen's investigational therapy, SNG001 (inhaled interferon-beta).
This collaboration, which builds on a long-standing relationship, unites Aerogen's world-class aerosol platform and manufacturing expertise with Synairgen's innovative drug development programme, aiming to provide targeted respiratory treatment for patients with severe viral infections, including critically ill patients requiring mechanical ventilation.
Synairgen's INVENT study, a large, global Phase 2 clinical trial, is investigating SNG001 in mechanically ventilated patients infected with a wide range of respiratory viruses such as influenza, respiratory syncytial virus, rhinovirus and COVID. The trial, which is being initiated across specialist clinical sites in US, UK and European countries, is designed to address the urgent need for effective therapies in this high-risk population, where mortality rates remain unacceptably high. The partnership with Aerogen seeks to ensure that SNG001 is delivered using a proven, hospital-trusted technology, optimising drug delivery and patient outcomes.
Joseph Colliver, CEO of Synairgen, commented: "Pairing SNG001 with Aerogen's advanced aerosol technology is a vital step in our mission to improve outcomes for critically ill respiratory patients. Aerogen's track record and technical leadership give us confidence that together, we can advance the development and delivery of this much-needed therapy. Moreover, the manufacturing, supply and exclusivity terms in our agreement are important for the future commercialisation of the product".
Aerogen will leverage its extensive intellectual property portfolio and scalable production capabilities to develop bespoke solutions to meet both clinical and commercial drug delivery device needs.
John Power, CEO and Founder of Aerogen, said: "This collaboration with Synairgen is a testament to Aerogen's commitment to innovation and strategic partnership in inhaled drug delivery. By uniting our technology to address the significant challenge of delivering biologics to the lungs of patients in an intensive care setting with Synairgen's cutting-edge potential therapeutic, we aim to accelerate the development of a much-needed inhaled treatment for critically ill respiratory patients."
Both companies share a vision of improving patient outcomes worldwide by combining specialised drug formulations with advanced delivery systems. The partnership reflects a growing trend in respiratory care, where integrated drug-device solutions are increasingly recognised as essential for clinical success.
About Synairgen Research Limited:
Headquartered in Southampton, UK, Synairgen is focused on developing an inhaled therapy for severe respiratory viral infections. SNG001, its investigational product, is a broad-spectrum antiviral designed to boost the lungs innate immune response. Synairgen has built an experienced focused, cross-functional team for the execution of trials such as INVENT, underscoring its commitment to advancing an innovative treatment for patients in critical care.
About Aerogen Ltd.:
Based on pioneering vibrating mesh technology, the Aerogen Solo vibrating mesh nebuliser has become the gold standard for respiratory patient care across the hospital from the emergency department to intensive care. With over 25 years of innovation, Aerogen's technology is trusted in more than 80 countries and has been used to treat over 30 million patients worldwide1. Known for its high-performance devices, such as the Aerogen Solo, the company continues to expand its reach and workforce, with significant investments in research and development. Aerogen remains committed to advancing education, research, and technology that support clinicians and improve patient outcomes in respiratory care.
Media Contacts:
Aerogen Ltd.: [email protected] | Tel: +353 91 540400
Synairgen: [email protected] | Tel: +44 (0) 23 8051 2800
For more information, please visit:
References:
1. Internal data on file.